-

ABIONYX Pharma: Half-Yearly Report on the Liquidity Contract with TP ICAP (Europe) SA

TOULOUSE, France--(BUSINESS WIRE)--Regulatory News:

Under the liquidity contract covering ABIONYX Pharma shares (FR0012616852 – ABNX FP) entrusted to TP ICAP (Europe), the following assets were included in the liquidity account on December 31, 2025:

  • Number of shares: 63,024
  • Cash balance: 250,951.67 €

During the 2nd half of 2025, a total of :

PURCHASE

437,203 shares

1,389,323.53 €

369 transactions

SALE

536,477 shares

1,560,333.66 €

502 transactions

As a reminder, at the half-yearly balance sheet dated June 30, 2025, the following assets were included in the liquidity account:

  • Number of shares: 162,298 shares
  • Cash balance: 86,279.52 €

When the liquidity contract was set up, the following resources were made available:

  • Number of shares: 131,000 shares
  • Cash balance: 40,801.20 €

ANNEX H2 2025

 

Purchases

Sales

ABNX FP

Number of transactions

Number of shares

Capital in EUR

Number of transactions

Number of shares

Capital in EUR

Total

369

437 203

1 389 323,53

502

536 477

1 560 333,66

20250701

1

1

1,19

3

2 902

3 492,92

20250702

1

1

1,21

2

224

271,49

20250703

2

2 271

2 707,06

2

2

2,44

20250704

1

1

1,21

1

1

1,21

20250707

1

1

1,21

1

1

1,21

20250708

1

1

1,21

1

1

1,21

20250709

1

1

1,19

1

1

1,19

20250710

1

1

1,21

1

1

1,21

20250711

1

1

1,21

2

1 781

2 172,81

20250714

1

1

1,22

2

32

39,17

20250715

1

1

1,23

1

1

1,23

20250716

1

1

1,23

1

1

1,23

20250717

1

1

1,23

1

1

1,23

20250718

1

1

1,23

2

2 211

2 746,05

20250721

1

1

1,26

2

153

193,08

20250722

1

1

1,25

1

1

1,25

20250723

1

1

1,26

5

8 691

11 045,44

20250724

1

1

1,30

5

12 291

16 286,42

20250725

3

3 681

4 900,69

4

7 551

10 418,87

20250728

1

1

1,39

11

30 861

44 685,19

20250729

3

4 551

6 939,43

11

23 541

38 883,67

20250730

7

16 231

28 984,31

1

1

1,85

20250731

11

26 661

43 396,07

1

1

1,75

20250801

5

8 061

12 270,79

5

8 409

13 719,53

20250804

1

1

1,63

9

22 381

37 265,25

20250805

3

3 082

5 176,63

5

8 621

15 063,56

20250806

1

1

1,73

4

3 162

5 499,94

20250807

6

13 921

22 958,52

1

1

1,74

20250808

6

11 283

17 654,04

1

1

1,61

20250811

1

1

1,60

6

16 139

26 625,15

20250812

1

1

1,67

1

1

1,67

20250813

1

1

1,82

5

8 561

15 592,26

20250814

2

3 041

5 552,91

6

9 801

18 728,69

20250815

3

4 441

8 081,58

3

2 471

4 694,90

20250818

1

1

1,85

5

7 381

13 761,45

20250819

1

1

1,90

5

6 761

13 001,38

20250820

1

1

1,92

2

1 041

1 994,56

20250821

1

1

1,91

4

4 111

7 922,95

20250822

1

1

1,92

11

16 261

33 277,95

20250825

1

1

2,15

11

12 341

28 080,35

20250826

9

29 511

61 139,20

4

2 261

5 134,54

20250827

1

1

2,06

11

15 911

35 190,61

20250828

1

1

3,00

11

12 281

36 843,00

20250829

3

4 451

12 561,07

11

9 471

29 076,87

20250901

1

1

3,58

11

8 281

30 366,58

20250902

11

21 591

88 354,20

5

2 251

10 356,40

20250903

7

11 071

39 819,29

3

1 321

5 059,59

20250904

1

1

3,67

9

9 931

37 813,67

20250905

6

9 721

35 058,97

2

146

554,77

20250908

10

17 481

58 490,32

1

1

3,67

20250909

2

1 071

3 288,01

3

4 301

15 058,31

20250910

5

4 381

15 945,72

2

1 111

4 210,62

20250911

1

1

3,69

10

16 481

63 688,84

20250912

2

1 741

6 624,56

5

5 471

21 652,16

20250915

1

1

4,05

7

7 691

31 674,55

20250916

2

1 951

7 999,10

1

1

4,10

20250917

3

2 701

10 539,33

1

1

3,93

20250918

5

7 061

26 397,84

4

1 418

5 548,50

20250919

1

1

3,98

4

3 861

15 370,43

20250922

4

4 521

16 592,07

4

3 551

13 974,17

20250923

1

1

3,90

2

741

2 897,30

20250924

2

2 151

8 238,42

5

4 321

17 201,42

20250925

3

2 981

11 542,61

2

701

2 775,91

20250926

8

11 691

42 489,70

1

1

3,80

20250929

1

1

3,65

1

1

3,65

20250930

6

8 666

27 625,95

3

1 801

6 087,45

20251001

1

1

3,30

5

5 201

17 679,60

20251002

4

4 031

14 056,97

1

1

3,57

20251003

1

1

3,50

2

961

3 363,50

20251006

4

3 981

13 425,80

3

1 941

6 793,50

20251007

3

2 571

8 573,54

1

1

3,34

20251008

1

1

3,36

5

6 041

20 796,66

20251009

3

2 661

9 086,46

3

1 901

6 672,66

20251010

4

3 981

13 624,80

1

1

3,50

20251013

1

1

3,31

6

7 491

25 790,01

20251014

4

4 201

14 399,15

1

1

3,45

20251015

1

1

3,36

7

9 231

32 617,96

20251016

2

694

2 415,21

3

1 681

6 014,02

20251017

3

2 941

10 387,78

1

1

3,58

20251020

5

6 851

23 172,65

5

5 071

18 272,75

20251021

6

9 251

29 989,79

1

1

3,39

20251022

1

1

3,60

11

16 811

60 519,60

20251023

4

4 571

16 671,75

5

4 621

17 702,95

20251024

1

1

3,80

10

11 221

44 748,50

20251027

4

3 720

14 789,73

10

8 961

38 919,58

20251028

1

1

4,55

11

9 141

43 405,35

20251029

9

17 141

80 006,34

5

2 491

12 793,24

20251030

7

10 551

45 404,28

1

1

4,48

20251031

5

6 161

25 646,05

5

4 551

20 164,05

20251103

3

2 641

10 780,86

5

4 691

20 122,46

20251104

3

2 791

11 169,73

6

5 701

24 018,23

20251105

6

8 891

35 906,45

1

1

4,15

20251106

1

1

3,93

10

12 201

50 259,43

20251107

3

4 101

17 236,46

5

3 771

16 503,76

20251110

4

4 481

18 568,60

2

681

2 914,60

20251111

1

1

4,18

4

2 941

12 445,78

20251112

7

10 501

42 742,65

5

4 111

18 133,25

20251113

3

2 821

11 148,77

3

1 581

6 434,67

20251114

2

291

1 155,34

4

1 631

6 663,64

20251117

1

1

4,28

5

4 631

19 850,73

20251118

3

2 871

11 949,27

1

1

4,17

20251119

1

1

4,22

3

1 541

6 572,62

20251120

3

2 821

11 769,34

3

1 481

6 361,14

20251121

1

1

4,35

9

9 551

42 161,65

20251124

4

4 901

20 063,60

1

1

4,20

20251125

1

1

4,18

5

4 061

17 465,18

20251126

5

6 881

29 098,30

1

1

4,30

20251127

3

2 224

9 072,46

1

1

4,08

20251128

2

2 111

8 528,48

1

1

4,08

20251201

4

4 241

17 022,46

1

1

4,06

20251202

4

4 071

15 973,93

1

1

4,03

20251203

5

6 181

23 005,50

1

1

3,80

20251204

1

1

3,79

5

5 881

22 765,19

20251205

1

1

3,91

3

1 851

7 265,61

20251208

1

1

3,90

1

1

3,90

20251209

3

2 671

10 208,65

2

891

3 483,75

20251210

4

3 951

14 989,23

1

1

3,83

20251211

4

3 851

14 083,72

1

1

3,72

20251212

4

3 721

13 236,49

2

1 011

3 710,29

20251215

1

1

3,53

2

1 051

3 731,03

20251216

4

3 721

12 713,02

1

1

3,42

20251217

9

12 721

39 905,26

1

1

3,16

20251218

1

1

3,20

6

9 481

31 218,90

20251219

1

1

3,41

6

8 501

29 709,51

20251222

5

5 991

20 522,54

1

1

3,54

20251223

1

1

3,40

4

4 381

15 331,30

20251224

1

1

3,49

3

2 111

7 462,79

20251225

0

0

0,00

0

0

0,00

20251226

0

0

0,00

0

0

0,00

20251229

3

2 591

8 925,20

2

1 011

3 568,80

20251230

2

1 831

6 408,52

5

6 101

22 274,12

20251231

1

1

3,67

6

7 291

27 527,77

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through breakthrough biotherapies that address life-threatening conditions with no effective treatments. Leveraging its proprietary apoA-I–based technology platform, ABIONYX Pharma develops innovative biologics and HDL-derived vectors that target the immune and inflammatory dysregulation underlying sepsis and other severe diseases. With a strong scientific foundation and a growing network of global clinical partners, ABIONYX Pharma aims to redefine the standard of care in sepsis and to bring critical care solutions to patients worldwide.

Contacts

ABIONYX Pharma
infos@abionyx.com

ABIONYX Pharma

BOURSE:ABNX
Release Versions
EnglishFrench

Contacts

ABIONYX Pharma
infos@abionyx.com

More News From ABIONYX Pharma

ABIONYX Pharma Carries Out a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today carries out a capital increase with the removal of preferential subscription rights (“PSR”) for certain categories of persons, for an amount of nearly 1.8 million euros through the issuance of 580,643 new sha...

ABIONYX Pharma Is Launching a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today announces the launch of a capital increase with the removal of preferential subscription rights (“PSR”) for certain categories of persons, for an amount of nearly 1.8 million euros through the issuance of 580...

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

TOULOUSE, France--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (Paris:ABNX): Market: Euronext Paris, Compartment C ISIN code: FR0012616852 Date Number of shares outstanding Total voting rights Total gross (1) Total net (2) November 30, 2025 34 931 012 44 816 425 44 600 800 (1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the b...
Back to Newsroom